GLP-1 agonists in type 1 diabetes-Reference-Cited by-同舟云学术

GLP-1 agonists in type 1 diabetes

Published:2013-12 Issue:3 Volume:149 Page:317-323
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Pettus Jeremy,Hirsch Irl,Edelman Steven

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference51 articles.

1. Most youth with type 1 diabetes in the T1D Exchange clinic registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines;Woods;Diabetes Care,2013

2. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses;Nauck;J. Clin. Endocrinol. Metab.,1986

3. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus;Nauck;J. Clin. Invest.,1993

4. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM;Nauck;Diabetologia,1996

5. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes;Bloomgarden;Endocr. Pract.,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LADA 30th anniversary: A growing form of diabetes with persistent unresolved questions;Diabetes/Metabolism Research and Reviews;2024-04-06

2. Latent autoimmune diabetes in adults: a focus on β-cell protection and therapy;Frontiers in Endocrinology;2022-08-05

3. The role of incretins and incretin-based drugs in autoimmune diseases;International Immunopharmacology;2021-09

4. Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Diabetes & Metabolism Journal;2021-05-31

5. Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation;Scientific Reports;2021-02-11